Endocrine Therapies in Breast and Prostate Cancer [electronic resource] /

It has been recognized for many years that cancers originating in the breast and prostate gland are frequently 'endocrine-dependent. ' Traditional thera­ pies included surgical endocrine ablative procedures or pharmacologic hor­ mone administration, both designed to antagonize the stimulatory effects of sex steroid hormones. In the past decade, several new treatment strategies for these tumors have emerged from basic studies in reproductive biology and mechanisms of action of steroid hormones. In some instances, these new treatments have elimin­ ated or reduced the need for major surgical ablative procedures or for toxic hormone therapy. The clinical role for other new treatments has not yet been clearly defined, although exciting preliminary data from recent clinical trials are now available. Thus, an objective review of the current status of these new therapeutic approaches is of interest. In this volume we have attempted to provide an in-depth review of both basic and clinical research involving several new treatment strategies for breast and prostate cancer. The first three chapters summarize preclinical and clinical studies of the luteinizing hormone-releasing hormone analogues, which can be used effectively to induce 'medical castration. ' Chapters 4, 5, and 6 review the rationale and clinical use of the compounds known collec­ tively as the aromatase inhibitors, which can also be used to suppress sex steroid hormone levels. Antiestrogen mechanism of action and its clinical implications for the design of innovative treatment approaches is considered in chapters 7 and 8.

Saved in:
Bibliographic Details
Main Authors: Osborne, C. Kent. editor., SpringerLink (Online service)
Format: Texto biblioteca
Language:eng
Published: Boston, MA : Springer US, 1988
Subjects:Medicine., Oncology., Medicine & Public Health.,
Online Access:http://dx.doi.org/10.1007/978-1-4613-1731-9
Tags: Add Tag
No Tags, Be the first to tag this record!
id KOHA-OAI-TEST:214646
record_format koha
institution COLPOS
collection Koha
country México
countrycode MX
component Bibliográfico
access En linea
En linea
databasecode cat-colpos
tag biblioteca
region America del Norte
libraryname Departamento de documentación y biblioteca de COLPOS
language eng
topic Medicine.
Oncology.
Medicine & Public Health.
Oncology.
Medicine.
Oncology.
Medicine & Public Health.
Oncology.
spellingShingle Medicine.
Oncology.
Medicine & Public Health.
Oncology.
Medicine.
Oncology.
Medicine & Public Health.
Oncology.
Osborne, C. Kent. editor.
SpringerLink (Online service)
Endocrine Therapies in Breast and Prostate Cancer [electronic resource] /
description It has been recognized for many years that cancers originating in the breast and prostate gland are frequently 'endocrine-dependent. ' Traditional thera­ pies included surgical endocrine ablative procedures or pharmacologic hor­ mone administration, both designed to antagonize the stimulatory effects of sex steroid hormones. In the past decade, several new treatment strategies for these tumors have emerged from basic studies in reproductive biology and mechanisms of action of steroid hormones. In some instances, these new treatments have elimin­ ated or reduced the need for major surgical ablative procedures or for toxic hormone therapy. The clinical role for other new treatments has not yet been clearly defined, although exciting preliminary data from recent clinical trials are now available. Thus, an objective review of the current status of these new therapeutic approaches is of interest. In this volume we have attempted to provide an in-depth review of both basic and clinical research involving several new treatment strategies for breast and prostate cancer. The first three chapters summarize preclinical and clinical studies of the luteinizing hormone-releasing hormone analogues, which can be used effectively to induce 'medical castration. ' Chapters 4, 5, and 6 review the rationale and clinical use of the compounds known collec­ tively as the aromatase inhibitors, which can also be used to suppress sex steroid hormone levels. Antiestrogen mechanism of action and its clinical implications for the design of innovative treatment approaches is considered in chapters 7 and 8.
format Texto
topic_facet Medicine.
Oncology.
Medicine & Public Health.
Oncology.
author Osborne, C. Kent. editor.
SpringerLink (Online service)
author_facet Osborne, C. Kent. editor.
SpringerLink (Online service)
author_sort Osborne, C. Kent. editor.
title Endocrine Therapies in Breast and Prostate Cancer [electronic resource] /
title_short Endocrine Therapies in Breast and Prostate Cancer [electronic resource] /
title_full Endocrine Therapies in Breast and Prostate Cancer [electronic resource] /
title_fullStr Endocrine Therapies in Breast and Prostate Cancer [electronic resource] /
title_full_unstemmed Endocrine Therapies in Breast and Prostate Cancer [electronic resource] /
title_sort endocrine therapies in breast and prostate cancer [electronic resource] /
publisher Boston, MA : Springer US,
publishDate 1988
url http://dx.doi.org/10.1007/978-1-4613-1731-9
work_keys_str_mv AT osborneckenteditor endocrinetherapiesinbreastandprostatecancerelectronicresource
AT springerlinkonlineservice endocrinetherapiesinbreastandprostatecancerelectronicresource
_version_ 1756269370222313472
spelling KOHA-OAI-TEST:2146462018-07-30T23:49:14ZEndocrine Therapies in Breast and Prostate Cancer [electronic resource] / Osborne, C. Kent. editor. SpringerLink (Online service) textBoston, MA : Springer US,1988.engIt has been recognized for many years that cancers originating in the breast and prostate gland are frequently 'endocrine-dependent. ' Traditional thera­ pies included surgical endocrine ablative procedures or pharmacologic hor­ mone administration, both designed to antagonize the stimulatory effects of sex steroid hormones. In the past decade, several new treatment strategies for these tumors have emerged from basic studies in reproductive biology and mechanisms of action of steroid hormones. In some instances, these new treatments have elimin­ ated or reduced the need for major surgical ablative procedures or for toxic hormone therapy. The clinical role for other new treatments has not yet been clearly defined, although exciting preliminary data from recent clinical trials are now available. Thus, an objective review of the current status of these new therapeutic approaches is of interest. In this volume we have attempted to provide an in-depth review of both basic and clinical research involving several new treatment strategies for breast and prostate cancer. The first three chapters summarize preclinical and clinical studies of the luteinizing hormone-releasing hormone analogues, which can be used effectively to induce 'medical castration. ' Chapters 4, 5, and 6 review the rationale and clinical use of the compounds known collec­ tively as the aromatase inhibitors, which can also be used to suppress sex steroid hormone levels. Antiestrogen mechanism of action and its clinical implications for the design of innovative treatment approaches is considered in chapters 7 and 8.1. Preclinical Studies and Antitumor Mechanism of Action of Luteinizing Hormone-Releasing Hormone Analogues -- 2. Luteinizing Hormone-Releasing Hormone Analogues in the Treatment of Prostate Cancer -- 3. Luteinizing Hormone-Releasing Hormone Agonists in the Treatment of Breast Cancer -- 4. Aromatase Inhibitors as New Endocrine Therapy for Breast Cancer -- 5. Clinical Use of Aromatase Inhibitors in the Treatment of Breast Cancer -- 6. Aminoglutethimide: Theoretical Considerations and Clinical Results in Advanced Prostate Cancer -- 7. Antiestrogen Therapy for Breast Cancer: Current Strategies and Future Prospects -- 8. Effects of Estrogens and Antiestrogens on Cell Proliferation: Implications for the Treatment of Breast Cancer -- 9. Flutamide and Other Antiandrogens in the Treatment of Advanced Prostatic Carcinoma -- 10. Progestational Agents in the Treatment of Breast Cancer.It has been recognized for many years that cancers originating in the breast and prostate gland are frequently 'endocrine-dependent. ' Traditional thera­ pies included surgical endocrine ablative procedures or pharmacologic hor­ mone administration, both designed to antagonize the stimulatory effects of sex steroid hormones. In the past decade, several new treatment strategies for these tumors have emerged from basic studies in reproductive biology and mechanisms of action of steroid hormones. In some instances, these new treatments have elimin­ ated or reduced the need for major surgical ablative procedures or for toxic hormone therapy. The clinical role for other new treatments has not yet been clearly defined, although exciting preliminary data from recent clinical trials are now available. Thus, an objective review of the current status of these new therapeutic approaches is of interest. In this volume we have attempted to provide an in-depth review of both basic and clinical research involving several new treatment strategies for breast and prostate cancer. The first three chapters summarize preclinical and clinical studies of the luteinizing hormone-releasing hormone analogues, which can be used effectively to induce 'medical castration. ' Chapters 4, 5, and 6 review the rationale and clinical use of the compounds known collec­ tively as the aromatase inhibitors, which can also be used to suppress sex steroid hormone levels. Antiestrogen mechanism of action and its clinical implications for the design of innovative treatment approaches is considered in chapters 7 and 8.Medicine.Oncology.Medicine & Public Health.Oncology.Springer eBookshttp://dx.doi.org/10.1007/978-1-4613-1731-9URN:ISBN:9781461317319